[
1. Edinoff A, Sathivadivel N, McBride T, Parker A, Okeagu C, Kaye A, et al. Chronic pain treatment strategies in Parkinson’s disease. Neurol Int. 2020;12(3):61-76.10.3390/neurolint12030014776853033218135
]Search in Google Scholar
[
2. Radhakrishnan DM, Goyal V. Parkinson’s disease: A review. Neurol India. 2018;66(Suppl S1):26-35.10.4103/0028-3886.22645129503325
]Search in Google Scholar
[
3. Pena-DIaz S, Ventura S. One ring is sufficient to inhibit α-synuclein aggregation. Neural Regen Res. 2022;17(3):508-11.10.4103/1673-5374.320973850437834380879
]Search in Google Scholar
[
4. Chagraoui A, Boulain M, Juvin L, Anouar Y, Barrière G, Deurwaerdère PD. L-DOPA in Parkinson’s disease: Looking at the “False” neurotransmitters and their meaning. Int J Mol Sci. 2020;21(1):294.10.3390/ijms21010294698163031906250
]Search in Google Scholar
[
5. Alborghetti M, Nicoletti F. Different generations of Type-B monoamine oxidase inhibitors in Parkinson’s disease: From bench to bedside. Curr Neuropharmacol. 2019;17(9):861-73.10.2174/1570159X16666180830100754705284130160213
]Search in Google Scholar
[
6. Song Z, Zhang J, Xue T, Yang Y, Wu D, Chen Z, et al. Different catechol-O-methyl transferase inhibitors in Parkinson’s disease: A bayesian network meta-analysis. Front Neurol. 2021;12:707723.10.3389/fneur.2021.707723849775134630283
]Search in Google Scholar
[
7. Li BD, Bi ZY, Liu JF, Si WJ, Shi QQ, Xue LP, at al. Adverse effects produced by different drugs used in the treatment of Parkinson’s disease: A mixed treatment comparison. CNS Neurosci Ther. 2017;23(10):827-42.10.1111/cns.12727649275728872217
]Search in Google Scholar
[
8. Mao Q, Qin WZ, Zhang A, Ye N. Recent advances in dopaminergic strategies for the treatment of Parkinson’s disease. Acta Pharmacol Sin. 2020;41(4):471-82.10.1038/s41401-020-0365-y747147232112042
]Search in Google Scholar
[
9. Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson’s disease: Efficacy and safety of current and new formulations. CNS Drugs. 2019;33(9):905-18.10.1007/s40263-019-00661-z677656331473980
]Search in Google Scholar
[
10. https://go.drugbank.com/ (access:11.05.2022)
]Search in Google Scholar
[
11. Stoker TB, Barker RA. Recent developments in the treatment of Parkinson’s Disease. F1000research. 2020;9:F1000 Faculty Rev-862.10.12688/f1000research.25634.1740068332789002
]Search in Google Scholar
[
12. Ghossein N, Kang M, Lakhkar AD. Anticholinergic medications. In: StatPearls [Internet]. Treasure Island (FL); 2021.
]Search in Google Scholar
[
13. Sharma VD, Lyons KE, Pahwa R. Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease. Ther Clin Risk Manag. 2018;14:665-73.10.2147/TCRM.S144481590549529695911
]Search in Google Scholar
[
14. https://clinicaltrials.gov/ (access:11.05.2022)
]Search in Google Scholar
[
15. Yang L, Wang H, Liu L, Xie A. The Role of Insulin/IGF-1/PI3K/Akt/GSK3β Signaling in Parkinson’s disease dementia. Front Neurosci. 2018;12:73.10.3389/fnins.2018.00073582621729515352
]Search in Google Scholar
